Here, we used the findings of a large pooled analysis and a prospective clinical trial in order to examine whether heparanase is associated with the outcome in breast cancer and to establish the role of heparanase in cell survival following chemotherapy in ER+ breast cancer. This evidence concerns the gene HPSE and breast carcinoma.